Q. Zuraw

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease

B. Maroni, Emil M Degoma, Mark T. Smith, 2017, American Journal of Nephrology.

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced

E. Soriano, A. Deodhar, W. Boehncke, 2021, RMD Open.

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus

K. Kalunian, T. Dörner, K. Lo, 2022, Annals of the Rheumatic Diseases.

Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study

P. Lipsky, G. Tsokos, K. Lo, 2021, The Journal of Rheumatology.

Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN)

V. Strand, P. Berry, C. Tolley, 2022, Lupus Science & Medicine.

Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE

J. Merrill, A. Askanase, Wei Tang, 2023, Lupus Science & Medicine.